Trade Editas Medicine - EDIT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.58 |
| Open | 1.55 |
| 1-Year Change | -70.86% |
| Day's Range | 1.48 - 1.55 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 1.51 | -0.08 | -5.03% | 1.59 | 1.59 | 1.48 |
| Apr 24, 2025 | 1.58 | 0.04 | 2.60% | 1.54 | 1.59 | 1.47 |
| Apr 23, 2025 | 1.53 | -0.13 | -7.83% | 1.66 | 1.67 | 1.52 |
| Apr 22, 2025 | 1.53 | 0.17 | 12.50% | 1.36 | 1.55 | 1.35 |
| Apr 21, 2025 | 1.31 | 0.09 | 7.38% | 1.22 | 1.37 | 1.21 |
| Apr 17, 2025 | 1.26 | 0.01 | 0.80% | 1.25 | 1.28 | 1.22 |
| Apr 16, 2025 | 1.24 | -0.07 | -5.34% | 1.31 | 1.31 | 1.23 |
| Apr 15, 2025 | 1.34 | 0.05 | 3.88% | 1.29 | 1.43 | 1.29 |
| Apr 14, 2025 | 1.29 | -0.01 | -0.77% | 1.30 | 1.31 | 1.16 |
| Apr 11, 2025 | 1.28 | 0.20 | 18.52% | 1.08 | 1.28 | 1.06 |
| Apr 10, 2025 | 1.07 | -0.02 | -1.83% | 1.09 | 1.11 | 1.02 |
| Apr 9, 2025 | 1.13 | 0.20 | 21.51% | 0.93 | 1.15 | 0.92 |
| Apr 8, 2025 | 0.96 | -0.06 | -5.88% | 1.02 | 1.05 | 0.93 |
| Apr 7, 2025 | 0.99 | 0.01 | 1.02% | 0.98 | 1.02 | 0.88 |
| Apr 4, 2025 | 1.02 | -0.06 | -5.56% | 1.08 | 1.13 | 1.00 |
| Apr 3, 2025 | 1.10 | -0.01 | -0.90% | 1.11 | 1.12 | 1.10 |
| Apr 2, 2025 | 1.16 | 0.05 | 4.50% | 1.11 | 1.20 | 1.10 |
| Apr 1, 2025 | 1.11 | -0.03 | -2.63% | 1.14 | 1.15 | 1.10 |
| Mar 31, 2025 | 1.14 | -0.06 | -5.00% | 1.20 | 1.20 | 1.13 |
| Mar 28, 2025 | 1.22 | -0.07 | -5.43% | 1.29 | 1.29 | 1.22 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Editas Medicine Company profile
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
11 Hurley St
CAMBRIDGE
MASSACHUSETTS 02141-2110
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com